Key result
An 8-week treatment with metformin significantly enhanced the L-arginine-induced decrease in systolic (12 vs 8 mmHg, P<0.05) and diastolic (9.5 vs 4.5 mmHg, P<0.01) blood pressure in NIDDM patients.
Why the study?
Does metformin improve hemodynamic and rheological responses to L-arginine in newly diagnosed NIDDM patients without vascular complications?
Population
10 newly diagnosed NIDDM patients with mild fasting hyperglycemia and without evidence of micro- and…
Comparison
Metformin 850 mg oral b.i.d. for 8 weeks… vs Pretreatment baseline test with intravenous…
Design
Cohort
Follow-up
8 weeks
Authors
Loading...
May enhance endothelial responses in early NIDDM; hypothesis-generating and requires RCT confirmation before practice implications.
Does metformin improve hemodynamic and rheological responses to L-arginine in newly diagnosed NIDDM patients without vascular complications?
Absolute Event Rate: 12% vs 8%
p-value: p=<0.05
Metformin amplifies the vasodilatory and rheological effects of L-arginine in newly diagnosed NIDDM patients, suggesting a potential mechanism for improving endothelial function.
Marfella et al. (1996) studied NIDDM (n=10). Metformin vs. Pretreatment baseline was evaluated on Maximal decrease in systolic blood pressure after L-arginine infusion (p=<0.05). An 8-week treatment with metformin significantly enhanced the L-arginine-induced decrease in systolic (12 vs 8 mmHg, P<0.05) and diastolic (9.5 vs 4.5 mmHg, P<0.01) blood pressure in NIDDM patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: